Pharma & HealthcareTop Companies
Pharma & Healthcare

Top Cell Sorting Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Pharma & Healthcare

Published

Feb 2026

Share:

Pharma & Healthcare

Top Cell Sorting Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
10.90 Billion
2026 Forecast (US$)
11.70 Billion
2032 Forecast (US$)
18.20 Billion
CAGR (2025-2032)
7.60%

Summary

The Cell Sorting market is entering a scale-up phase, driven by precision medicine, immunotherapy, and high-throughput research demands. Leading Cell Sorting market companies consolidate share through advanced flow cytometry platforms, proprietary reagents, and integrated automation. With the market rising from US$ 10.90 Billion in 2025 to US$ 18.20 Billion by 2032, a 7.60% CAGR underpins sustained strategic investment.

2025 Revenue of Top Cell Sorting Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

The ranking of Cell Sorting market companies is based on a composite scoring model combining quantitative and qualitative indicators. Quantitatively, we evaluate estimated 2025 Cell Sorting revenue, multi-year growth trajectory, installed instrument base, and geographic diversification. Qualitatively, we assess technology differentiation in flow and microfluidic sorting, breadth of reagents and consumables portfolio, automation and software capabilities, and depth of service and application-support networks. Additional weight is assigned to recurring revenue intensity, regulatory track record, participation in landmark clinical and translational research projects, and ability to secure long-duration service and maintenance contracts. Strategic moves in 2025-2026—such as acquisitions, co-development alliances with biopharma, and platform upgrades—are incorporated through a strategic momentum score. Each company receives normalized scores per criterion; final rankings reflect the weighted aggregate, ensuring objective, comparable positioning across global incumbents and emerging specialists.

Top 10 Companies in Cell Sorting

1
BD (Becton, Dickinson and Company)
Operations in 190+ countries with strong hospital and research institute penetration
Franklin Lakes, USA
High-parameter flow cytometry, clinical-grade sorting, integrated workflows
Flow cytometry cell sorters, reagents, informatics solutions
Expanded high-color spectral sorting portfolio and deepened partnerships with leading immuno-oncology centers
US$ 2.10 Billion (estimated)
2
Sony Biotechnology Inc.
Strong presence in North America, Europe, and Asia-Pacific academic centers
San Jose, USA (Sony Group Corporation, Japan)
Compact, automated cell sorters and spectral detection technology
Benchtop cell sorters, spectral cytometry, research reagents
Launched next-generation microfluidic sorter and expanded OEM partnerships with life-science tool providers
US$ 0.85 Billion (estimated)
3
Beckman Coulter Life Sciences (Danaher Corporation)
Installed base across clinical labs and pharma R&D globally
Indianapolis, USA
High-throughput sorting integrated with lab automation platforms
Flow cytometers, cell sorters, automation systems
Enhanced data analytics suite and partnered with CDMOs for cell-therapy manufacturing workflows
US$ 0.80 Billion (estimated)
4
Miltenyi Biotec
Strong footprint in Europe and growing presence in cell-therapy manufacturing worldwide
Bergisch Gladbach, Germany
MACS magnetic sorting, closed-system cell processing
Magnetic cell sorting, flow-based sorters, cell-therapy tools
Expanded GMP-compliant solutions and co-development agreements with CAR-T and gene-therapy developers
US$ 0.72 Billion (estimated)
5
Cytiva (Danaher Corporation)
Strong in biopharma, CDMO, and advanced therapy ecosystems
Marlborough, USA
Integrated upstream to cell characterization workflows
Cell analysis, bioprocess tools, cell isolation systems
Strengthened cell-therapy innovation centers and introduced modular cell isolation platforms
US$ 0.60 Billion (estimated)
6
Bio-Rad Laboratories, Inc.
Broad reach across translational research and clinical labs
Hercules, USA
High-sensitivity detection and multiplexing assay integration
Flow cytometry, droplet digital platforms, reagents
Added AI-enabled analysis tools and advanced immunology panel solutions
US$ 0.55 Billion (estimated)
7
Thermo Fisher Scientific Inc.
Comprehensive global sales and service infrastructure
Waltham, USA
End-to-end workflows from sample prep to analysis
Cell analysis instruments, reagents, lab automation
Integrated cell sorting into cloud-connected lab ecosystems and expanded oncology research collaborations
US$ 0.50 Billion (estimated)
8
Sysmex Corporation
Strong in Asia-Pacific hospital and reference lab networks
Kobe, Japan
Clinical diagnostic integration with cell analysis
Diagnostic analyzers, flow-based cell analysis and sorting
Launched advanced hematology-linked sorting workflows targeting minimal residual disease assessment
US$ 0.42 Billion (estimated)
9
NAMOCELL Inc. (A Bio-Techne Brand)
Growing presence in genomics and single-cell sequencing labs globally
Mountain View, USA
Gentle, low-pressure single-cell sorting for omics workflows
Single-cell microfluidic sorters
Broadened compatibility with leading single-cell sequencing platforms and expanded distributor network
US$ 0.18 Billion (estimated)
10
On-Chip Biotechnologies Co., Ltd.
Selective footprint in Asia, Europe, and North America research institutes
Tokyo, Japan
Non-droplet microfluidic sorting for fragile cells and rare populations
Microfluidic-based cell sorters
Strengthened collaborations in regenerative medicine and launched upgraded microfluidic chips for rare-cell isolation
US$ 0.12 Billion (estimated)

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

BD (Becton, Dickinson and Company)

BD is a global life-science leader delivering comprehensive flow cytometry and cell sorting solutions for clinical, translational, and basic research applications.

Key Financials: 2025 Cell Sorting revenue US$ 2.10 Billion; R&D intensity about 8.50% of segment revenue.
Flagship Products: BD FACSAria Fusion, BD FACSMelody, BD FACSymphony S6
2025-2026 Actions: Invested in spectral flow upgrades, expanded automation partnerships, and deepened collaborations with major immuno-oncology consortia.
Three-line SWOT: Extensive installed base and clinical trust; Complex portfolio can complicate purchasing decisions; Opportunity—growing use of high-color sorting in cell and gene therapy.
Notable Customers: MD Anderson Cancer Center, Mayo Clinic, leading national reference laboratories worldwide
2

Sony Biotechnology Inc.

Sony Biotechnology provides compact, high-performance cell sorters and spectral cytometry systems aimed at flexible deployment in research laboratories worldwide.

Key Financials: 2025 Cell Sorting revenue US$ 0.85 Billion; segment CAGR estimated at 9.20% through 2032.
Flagship Products: Sony MA900 Cell Sorter, Sony SH800S Cell Sorter, Sony ID7000 Spectral Analyzer
2025-2026 Actions: Introduced next-gen microfluidic sorter, expanded service coverage in Europe, and accelerated OEM technology licensing deals.
Three-line SWOT: Strong brand and engineering capabilities; Smaller clinical installed base than BD; Opportunity—demand for compact, automated sorters in decentralized research environments.
Notable Customers: Stanford University, Karolinska Institute, leading immunology and stem-cell research centers
3

Beckman Coulter Life Sciences (Danaher Corporation)

Beckman Coulter Life Sciences delivers advanced flow cytometry and cell sorting systems integrated with lab automation for high-throughput environments.

Key Financials: 2025 Cell Sorting revenue US$ 0.80 Billion; operating margin estimated around 17.40%.
Flagship Products: MoFlo Astrios, CytoFLEX SRT, BioLector XT integration solutions
2025-2026 Actions: Enhanced automation interfaces, launched analytics upgrades, and partnered with CDMOs to refine cell-therapy manufacturing workflows.
Three-line SWOT: Strong automation integration and industrial reliability; Less presence in early-stage startups; Opportunity—scale-up of cell-therapy and bioprocessing facilities globally.
Notable Customers: Lonza, Thermo Fisher CDMO clients, major pharmaceutical R&D centers
4

Miltenyi Biotec

Miltenyi Biotec specializes in magnetic cell separation and cell-processing platforms serving research and clinical cell-therapy applications.

Key Financials: 2025 Cell Sorting revenue US$ 0.72 Billion; double-digit growth in cell-therapy solutions above 12.00% CAGR.
Flagship Products: MACSQuant Tyto, autoMACS Pro Separator, CliniMACS Prodigy
2025-2026 Actions: Scaled GMP-compliant offerings, expanded manufacturing capacity, and deepened partnerships with CAR-T and gene-therapy developers.
Three-line SWOT: Unique magnetic closed systems; Higher capital cost versus basic flow sorters; Opportunity—industrialization of autologous and allogeneic cell therapies.
Notable Customers: Novartis, Kite Pharma, leading academic cell-therapy centers
5

Cytiva (Danaher Corporation)

Cytiva offers integrated solutions that link cell culture, processing, and analytical cell sorting for biopharmaceutical and advanced-therapy developers.

Key Financials: 2025 Cell Sorting revenue US$ 0.60 Billion; recurring revenue share above 55.00% from consumables and services.
Flagship Products: ÄKTA Cell Culture-linked systems, cell isolation and analysis platforms, imaging-enabled sorters
2025-2026 Actions: Strengthened cell-therapy innovation labs, introduced modular isolation platforms, and expanded co-development projects with CDMOs.
Three-line SWOT: Deep bioprocess integration; Less focus on standalone cytometry research segment; Opportunity—end-to-end solutions for advanced-therapy manufacturing.
Notable Customers: Sartorius-partnered CDMOs, global biopharma majors, leading CGT developers
6

Bio-Rad Laboratories, Inc.

Bio-Rad serves translational researchers with cell sorting, multiplex immunoassays, and digital PCR, enabling high-sensitivity immune monitoring workflows.

Key Financials: 2025 Cell Sorting revenue US$ 0.55 Billion; R&D spend approximately 9.80% of life-science segment revenue.
Flagship Products: S3e Cell Sorter, ZE5 Cell Analyzer, Droplet Digital platforms
2025-2026 Actions: Integrated AI-assisted analysis, refreshed immunophenotyping panels, and expanded collaborations in autoimmunity and oncology research.
Three-line SWOT: Strong assay ecosystem; Smaller clinical cytometry footprint; Opportunity—integration of cell sorting with molecular readouts in multi-omics studies.
Notable Customers: National Institutes of Health labs, major university medical centers, biotech discovery teams
7

Thermo Fisher Scientific Inc.

Thermo Fisher delivers broad life-science solutions, including cell sorting, consumables, and digital infrastructure, targeting end-to-end laboratory workflows.

Key Financials: 2025 Cell Sorting revenue US$ 0.50 Billion; integrated solutions growth tracking around 8.60% CAGR.
Flagship Products: Attune Cell Analyzer-based sorters, Invitrogen cell analysis reagents, automation platforms
2025-2026 Actions: Linked sorters to cloud-based lab management, expanded oncology and immune-monitoring partnerships, and increased footprint in emerging markets.
Three-line SWOT: Comprehensive portfolio and scale; Cell sorting not always core focus; Opportunity—bundle cell sorting with broader lab digitization projects.
Notable Customers: Global CRO networks, top-ten pharmaceutical companies, regional cancer centers
8

Sysmex Corporation

Sysmex combines diagnostic excellence with advanced cell analysis systems, targeting hospitals and reference labs integrating flow-based sorting.

Key Financials: 2025 Cell Sorting revenue US$ 0.42 Billion; strong Asia-Pacific growth above 10.10% CAGR.
Flagship Products: Cell analysis and sorting modules integrated with hematology analyzers, clinical flow platforms
2025-2026 Actions: Introduced MRD-focused workflows, deepened collaborations with oncology centers, and expanded service coverage across Asia.
Three-line SWOT: Diagnostic integration strength; Limited presence in basic research; Opportunity—clinical adoption of flow-based residual disease monitoring.
Notable Customers: Leading Japanese university hospitals, regional cancer institutes, high-volume reference laboratories
9

NAMOCELL Inc. (A Bio-Techne Brand)

NAMOCELL focuses on gentle single-cell microfluidic sorters optimized for genomics, single-cell sequencing, and cell-line development.

Key Financials: 2025 Cell Sorting revenue US$ 0.18 Billion; high-growth niche with CAGR above 15.00%.
Flagship Products: Namo Single Cell Dispenser Series, microfluidic-based gentle sorters
2025-2026 Actions: Expanded compatibility with leading single-cell omics platforms and strengthened global distributor footprint.
Three-line SWOT: Highly differentiated single-cell focus; Smaller installed base and service network; Opportunity—surging demand in single-cell genomics and CRISPR workflows.
Notable Customers: 10x Genomics ecosystem labs, leading genomics institutes, biotech cell-line development teams
10

On-Chip Biotechnologies Co., Ltd.

On-Chip Biotechnologies develops microfluidic cell sorters tailored for fragile and rare cells in regenerative medicine and microbiology.

Key Financials: 2025 Cell Sorting revenue US$ 0.12 Billion; revenue mix heavily skewed to instruments at about 70.00%.
Flagship Products: On-chip Sort series, customized microfluidic sorting chips
2025-2026 Actions: Refined rare-cell isolation capabilities, expanded collaborations in regenerative medicine, and pursued distributor-led expansion in Europe and North America.
Three-line SWOT: Unique non-droplet microfluidics; Limited brand recognition globally; Opportunity—growing interest in gentle sorting for stem-cell and microbiome research.
Notable Customers: Japanese regenerative medicine centers, European stem-cell labs, cutting-edge microbiology research groups

SWOT Leaders

BD (Becton, Dickinson and Company)

SWOT Snapshot

SWOT
Strengths

Largest installed base, deep clinical trust, broad reagent ecosystem, and strong global service coverage.

Weaknesses

Complex product portfolio, relatively higher system pricing, and slower refresh cycles for some legacy platforms.

Opportunities

Rising adoption of high-parameter sorting in immuno-oncology, cell therapy, and translational research globally.

Threats

Intensifying competition from agile innovators and pricing pressure in cost-sensitive emerging markets.

Sony Biotechnology Inc.

SWOT Snapshot

SWOT
Strengths

Compact, user-friendly systems, spectral technology leadership, and strong brand association with precision engineering.

Weaknesses

Smaller clinical presence and more limited service infrastructure than traditional diagnostics giants.

Opportunities

Growing demand for benchtop, automated sorters in decentralized research and core facility environments worldwide.

Threats

Competitive responses from larger incumbents and rapid innovation cycles in microfluidic and single-cell technologies.

Beckman Coulter Life Sciences (Danaher Corporation)

SWOT Snapshot

SWOT
Strengths

High-throughput platforms, automation integration expertise, and strong relationships with industrial bioprocess customers.

Weaknesses

Perceived complexity of systems for smaller labs and slower penetration into early-stage start-up ecosystems.

Opportunities

Scale-up of cell-therapy manufacturing and integration of sorting with end-to-end bioprocess solutions.

Threats

Emerging microfluidic alternatives and budget constraints in research institutions limiting large capital purchases.

Cell Sorting Market Regional Competitive Landscape

North America remains the largest market, driven by strong NIH funding, vibrant biotech clusters, and rapid immuno-oncology adoption. BD, Beckman Coulter Life Sciences, Thermo Fisher, and Bio-Rad lead instrument and reagent placements, while specialized Cell Sorting market companies such as NAMOCELL capture share in single-cell and CRISPR-intensive labs.

Europe shows balanced demand across academic, hospital, and industrial users, supported by EU framework programs and national cancer initiatives. Miltenyi Biotec leverages its German base to dominate magnetic cell sorting, while BD, Sony Biotechnology, and Cytiva expand integrated workflows. Regulatory focus on data integrity favors established Cell Sorting market companies with validated software suites.

Asia-Pacific is the fastest-growing region, underpinned by expanding biomedical hubs in China, Japan, South Korea, and Singapore. Sysmex and Sony Biotechnology benefit from proximity and strong local relationships, while BD and Thermo Fisher scale premium platforms. Competitive pricing pressure is intense, enabling nimble Cell Sorting market companies and regional OEMs to penetrate mid-tier institutions.

Latin America and the Middle East & Africa remain smaller but strategically important for long-term volume growth. Budget constraints favor mid-range and refurbished systems, yet reference centers increasingly demand high-parameter sorters from BD, Beckman Coulter, and Bio-Rad. Partnerships with local distributors are critical, giving agile Cell Sorting market companies opportunities to differentiate through service.

In China, government-backed cell-therapy and genomics initiatives accelerate adoption of high-end sorters and microfluidic platforms. Global leaders such as BD, Cytiva, and Thermo Fisher compete with domestic Cell Sorting market companies offering cost-effective alternatives. Local manufacturing, regulatory familiarity, and tailored service models are becoming decisive competitive factors.

Regional core facilities and shared technology platforms across universities are reshaping procurement, favoring scalable, multipurpose sorters and robust service agreements. This trend benefits diversified Cell Sorting market companies like BD, Beckman Coulter, and Sony Biotechnology, while creating entry points for specialist microfluidic and single-cell players that can plug into shared infrastructure.

Cell Sorting Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

DeepSort Analytics
Disruptor
USA

Cloud-native AI platform that overlays existing sorters from leading Cell Sorting market companies to optimize gating strategies, reduce run times, and standardize results across sites.

MicroFlow Dynamics
Disruptor
Germany

Developer of ultra-low-shear microfluidic cell sorters designed for fragile stem cells and organoids, targeting GMP-compliant regenerative medicine workflows.

CytoNova Labs
Disruptor
India

Offers affordable, modular flow-based sorters with open-source analysis software, aimed at democratizing access in emerging markets and teaching hospitals.

OptiSpectra BioSystems
Disruptor
United Kingdom

Combines spectral cytometry with advanced photonics to deliver compact, high-parameter sorters positioned against premium platforms from incumbent Cell Sorting market companies.

GenCellis Technologies
Disruptor
South Korea

Focuses on integrated single-cell prep-to-sequencing workcells, coupling gentle microfluidic sorting with library preparation automation for genomics core facilities.

Cell Sorting Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Cell Sorting market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Cell Sortingmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.